Company profile
Ventyx Biosciences company profile
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Business identity
- Website
- http://www.ventyxbio.com
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 101-250 employees
- Revenue range
- $50,000+
- Founded
- 2018-01-01, Year
Headquarters
- Headquarters
- Wonewoc, Wisconsin, United States
- Country code
- US
- Continent
- North America